DPDaily Peptide

SS-31 · DECODED

← Back to Decoded
FDA APPROVED · BARTH SYNDROMEMITOCHONDRIAL STABILIZERALL OTHER USE OFF-LABEL

SS-31

Decoded · FDA Approved (Barth Syndrome) · Forzinity

FDA approved. For a condition affecting approximately 130 people in the United States. SS-31 (elamipretide, brand name Forzinity) received FDA Accelerated Approval on September 19, 2025 for Barth syndrome, a rare genetic mitochondrial disorder. Every use outside that specific indication is off-label extrapolation. The grey market is running ahead of the evidence on longevity and performance applications.

BY THE NUMBERS

4
AMINO ACIDS · AROMATIC-CATIONIC TETRAPEPTIDE
Sep 19, 2025
DATE OF FDA ACCELERATED APPROVAL (FORZINITY)
~130
US PATIENTS WITH BARTH SYNDROME · VERY RARE INDICATION
0
APPROVED INDICATIONS BEYOND BARTH SYNDROME

HOW IT WORKS

Selectively targets and binds cardiolipin, a phospholipid critical to the structural integrity of the inner mitochondrial membrane. This stabilizes the respiratory chain complexes (particularly Complex I and Complex III), reduces mitochondrial reactive oxygen species (ROS) generation, and improves ATP synthesis efficiency. The FDA's 2025 accelerated approval for Barth syndrome (a disease of cardiolipin metabolism) clinically validates this mechanism.

WHERE IT CAME FROM

SS-31, also known by the INN name elamipretide, is a synthetic four-amino acid peptide developed by Hazel Szeto and Peter Schiller at Cornell University in the early 2000s. The 'SS' in the name stands for Szeto-Schiller. It belongs to a class called aromatic-cationic peptides: the alternating positive charges and aromatic rings allow it to penetrate cell membranes and concentrate selectively in the inner mitochondrial membrane, where it interacts with cardiolipin.

Cardiolipin is a unique phospholipid found almost exclusively in the inner mitochondrial membrane that is critical to mitochondrial structure and electron transport chain function. In disease states such as mitochondrial disorders, heart failure, and aging, cardiolipin is damaged or depleted and mitochondrial function declines. SS-31 stabilizes cardiolipin and the electron transport chain complexes it supports, reducing oxidative damage and improving mitochondrial efficiency. This mechanism is well-characterized at the molecular level and forms the basis for Forzinity's FDA approval in Barth syndrome, a rare genetic disorder in which cardiolipin metabolism is fundamentally impaired.

THE STUDIES

Sep 19, 2025
FDA Accelerated Approval: Barth Syndrome (Forzinity): Stealth BioTherapeutics received FDA Accelerated Approval for elamipretide (Forzinity) on September 19, 2025, for the treatment of Barth syndrome. Barth syndrome is a rare X-linked genetic disorder caused by mutations in the tafazzin gene, resulting in abnormal cardiolipin remodeling that impairs mitochondrial function throughout the body, particularly in cardiac and skeletal muscle. The MMPOWER-3 trial was the primary Phase 3 registration trial. The original primary endpoint (six-minute walk test distance) did not reach statistical significance. FDA granted approval based on knee-extensor strength improvement observed in an extended follow-up period. Approximately 130 patients have Barth syndrome in the United States.
Phase 2
Heart failure trials (PROGRESS-HF and related Phase 2 trials): SS-31 has been investigated in Phase 2 trials for heart failure with reduced ejection fraction, targeting the mitochondrial dysfunction that characterizes the failing heart. PROGRESS-HF (n=71) was the primary Phase 2 heart failure trial; it missed its primary endpoint in 2020. Related Phase 2 studies examined mitochondrial and functional measures in some outcomes. These trials did not advance to Phase 3 registration for heart failure. Phase 2 results are supportive of the mechanistic hypothesis but not definitive, and SS-31 is not approved for heart failure.
Phase 2
Renal and mitochondrial myopathy trials: Phase 2 studies examined SS-31 in acute kidney injury and mitochondrial myopathy, a group of muscle diseases caused by mitochondrial dysfunction. The renal data showed improvement in mitochondrial density and some functional kidney measures. Mitochondrial myopathy data showed functional improvement in small studies. These are Phase 2 results in specific patient populations, not evidence for performance enhancement or longevity benefit in healthy individuals.

WHAT THE STUDIES SHOW

FDA APPROVED

  • ▸Barth syndrome treatment (FDA Accelerated Approval Sep 2025)
  • ▸Cardiolipin stabilization mechanism: confirmed and well-characterized
  • ▸Knee-extensor strength improvement in Barth syndrome (extended follow-up)
  • ▸Forzinity is available through prescription for the approved indication

PHASE 2 (NOT APPROVED)

  • ▸Heart failure: Phase 2 functional improvements, no Phase 3 completion
  • ▸Renal protection: mitochondrial density improvement in AKI studies
  • ▸Mitochondrial myopathy: small Phase 2 functional data
  • ▸All Phase 2 data is in disease populations, not healthy individuals

OFF-LABEL / UNPROVEN

  • ▸Longevity or anti-aging benefit in healthy people: no trial data
  • ▸Performance enhancement: no controlled human data
  • ▸Cognitive benefits: mechanistic speculation only
  • ▸Grey market longevity use is extrapolation beyond what any trial has tested

SIDE EFFECTS

FROM CLINICAL TRIALS

  • ▸Injection site reactions (primary administration route is subcutaneous)
  • ▸Injection site pain and bruising
  • ▸Fatigue (reported in some trial participants)
  • ▸Generally well-tolerated in trial populations

NOTABLE / MONITOR FOR

  • ▸Mitochondrial modulation at supraphysiologic doses: consequences in healthy individuals unknown
  • ▸All trial safety data is from patient populations with mitochondrial disease, not healthy adults
  • ▸Grey market supply: unverified purity and concentration outside regulated manufacturing
  • ▸MMPOWER-3 original primary endpoint did not reach significance. The approval basis was a secondary endpoint.

REGULATORY STATUS

FDA STATUS
FDA Accelerated Approval · Barth Syndrome ONLY · Forzinity
PHASE
Approved for Barth syndrome · Phase 2 for heart failure (not approved) · Other indications investigational
PROJECTED NDA
Stealth BioTherapeutics pursuing additional indications · Timeline unconfirmed

SS-31 (elamipretide) received FDA Accelerated Approval on September 19, 2025 under the brand name Forzinity for the treatment of Barth syndrome. Accelerated Approval means the drug was approved based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit (in this case, knee-extensor strength) while confirmatory evidence of clinical benefit is still being established. This is an FDA approval for a specific and serious rare disease. It does not extend to anti-aging, longevity, performance enhancement, or any other indication. All off-label and grey market longevity use of SS-31 is operating beyond the scope of any approved or Phase 3-validated evidence.

PROS & CONS

PROS

  • +FDA Accelerated Approval means SS-31 has completed Phase 3 trial submission and regulatory review — a process none of the other longevity compounds in this series have completed
  • +Cardiolipin stabilization mechanism is well-characterized and scientifically novel
  • +Phase 2 data in multiple disease populations (heart failure, kidney, myopathy) provides supportive evidence for broader mitochondrial effects
  • +Mechanism-first credibility: the target is real, the pharmacology is sound
  • +Not WADA banned (as of current review)

CONS

  • −Approved for one of the rarest conditions in the US (~130 patients)
  • −MMPOWER-3 original primary endpoint did not reach significance
  • −All trial data is from disease populations, not healthy adults
  • −Longevity and performance use: zero controlled human trial data
  • −Grey market SS-31: unverified relative to the approved Forzinity product
  • −Accelerated Approval requires confirmatory evidence. Long-term benefit not yet fully established.

DAILY PEPTIDE VERDICT

RANKING

FDA Approved. Narrowly Indicated.

SS-31 is the only longevity compound in this series with an FDA approval and a Phase 3 trial record. The Barth syndrome approval is narrow and the condition is rare, but the process required — trial submission, review, approval — distinguishes it factually from compounds at preclinical or observational evidence stages. The mechanism, cardiolipin stabilization in mitochondria, is scientifically sound and relevant to aging biology broadly. The honest statement about the grey market longevity use is: the mechanism is interesting, the Barth syndrome data is real, and the Phase 2 signals in heart failure and kidney disease are supportive. None of that is controlled evidence that SS-31 extends lifespan or enhances performance in healthy people. The jump from 'fixes a rare mitochondrial disease' to 'longevity compound' is a meaningful extrapolation that grey market users are making without human trial support.

Also in LONGEVITY

// LONGEVITY

MOTS-c

GREY MARKETPRECLINICAL

// LONGEVITY

Epitalon

GREY MARKETPRECLINICAL

Khavinson group data only · No Western clinical trials

DISCLAIMER · EDUCATIONAL USE ONLY

This document is for educational and informational purposes only. SS-31 is an FDA-approved pharmaceutical. Prescribing, dosing, and clinical application are the purview of a licensed healthcare provider. Information here synthesizes publicly available clinical data and does not constitute medical advice.